A phase II clinical trial (NCT04050462) is ongoing with an anti-CXCL8 antibody (BMS-986253) in combination with nivolumab (anti-PD-1 antibody) in patients with advanced hepatocellular carcinoma (HCC). This evidence concerns the gene CXCL8 and hepatocellular carcinoma.